An Observational Study of Patients With Chronic Liver Disease

NCT05744713 · tracked via the Priya Life Science USA tracker

Sponsor

Target PharmaSolutions, Inc.

Phase

Observational

Started

2024-02-19

Last updated

2026-03-03

Condition(s) studied

Chronic Liver DiseaseCirrhosis

Investigational drug(s) / intervention(s)

Observational

Observational: Observational

Study summary

TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: Disease Cohort •Adult\* patients at the time of enrollment with a diagnosis of CLD/cirrhosis by ICD-10 code in the EHR interface Engaged Cohort * Adult\* patients diagnosed and managed for CLD/cirrhosis invited to participate * Ability to provide written informed consent Exclusion Criteria: Disease Cohort * Death * Manual removal (sponsor or site request) * No EHR interface encounter \> 3 years. Engaged Cohort * Patient expressed desire to withdraw consent to complete PROs * Failure to complete PROs within 24 weeks of initial invitation * Greater than 24 months lapse of survey completion after baseline surveys completed * Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.

Primary outcome measure(s)

To characterize the natural history of disease in patients with CLD from various etiologies and Cirrhosis — 20 Years
To assess safety and effectiveness of CLD/Cirrhosis treatments and treatments for complications of any chronic liver disease — 20 Years
To establish learning health networks focused on quality of care for patients — 20 Years

Trial sites (10)

Facility	City	Region
Keck School of Medicine of USC	Los Angeles	California
Stanford Medicine	Redwood City	California
Georgetown Medstar Transplant Institute	Washington D.C.	District of Columbia
Rush University Medical Center	Chicago	Illinois
Columbia University Irving Medical Center/ New York Presbyterian Hospital	New York	New York
Atrium Health Center for Liver Disease and Transplant	Charlotte	North Carolina
University of Pennsylvania	Philadelphia	Pennsylvania
Temple University - Lewis Katz School of Medicine	Philadelphia	Pennsylvania
Baylor Scott & White Research Institute	Dallas	Texas
Baylor College of Medicine	Houston	Texas

More Target PharmaSolutions, Inc. trials in the USA

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Active, not recruiting

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease Active, not recruiting

An Observational Study of Patients With Chronic Gastrointestinal Disease Active, not recruiting

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC Active, not recruiting

An Observational Study of Patients With Dermatologic Disease Starting soon

Other trials for the same condition

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease Recruiting

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk Active, not recruiting

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis Recruiting

Endoscopic Ultrasound Shear Wave Elastography Study Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05744713 on ClinicalTrials.gov ↗ ← All trials in the USA